Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer: A network meta-analysis.

Fu ZZ, Li K, Peng Y, Zheng Y, Cao LY, Zhang YJ, Sun YM.

Medicine (Baltimore). 2017 Jan;96(2):e5853. doi: 10.1097/MD.0000000000005853. Review.

2.

Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.

Wang W, Hou X, Yan J, Shen J, Lian X, Sun S, Liu Z, Meng Q, Wang D, Zhao M, Qiu J, Hu K, Zhang F.

BMC Cancer. 2017 Aug 1;17(1):510. doi: 10.1186/s12885-017-3503-2.

3.

Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.

Sun W, Wang T, Shi F, Wang J, Wang J, Hui B, Zhang Y, Lu J, Chen H, Liu Z.

BMC Cancer. 2015 May 4;15:353. doi: 10.1186/s12885-015-1355-1.

4.

Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network meta-analysis.

Wang XF, Huang WF, Nie J, Zhou Y, Tan DW, Jiang JH.

J Cell Biochem. 2018 Jul;119(7):5082-5103. doi: 10.1002/jcb.26266. Epub 2018 Apr 6.

PMID:
28681936
5.

Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.

Liu GF, Li GJ, Zhao H.

J Cell Biochem. 2018 Jan;119(1):511-523. doi: 10.1002/jcb.26210. Epub 2017 Jul 17. Review.

PMID:
28608558
6.

[Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma].

Zeng SY, Li LY, Shu KY, Pan M, Li HP, Luo B.

Ai Zheng. 2008 Sep;27(9):942-6. Chinese.

PMID:
18799032
7.

Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.

Iocca O, Farcomeni A, Di Rocco A, Di Maio P, Golusinski P, Pardiñas López S, Savo A, Pellini R, Spriano G.

Oral Oncol. 2018 May;80:40-51. doi: 10.1016/j.oraloncology.2018.03.001. Epub 2018 Mar 27.

PMID:
29706187
8.

Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.

Kagabu M, Shoji T, Murakami K, Omi H, Honda T, Miura F, Yokoyama Y, Tokunaga H, Takano T, Ohta T, Shimizu D, Sato N, Soeda S, Watanabe T, Yamada H, Mizunuma H, Yaegashi N, Nagase S, Tase T, Sugiyama T.

Int J Clin Oncol. 2016 Aug;21(4):735-740. doi: 10.1007/s10147-016-0946-4. Epub 2016 Jan 19.

PMID:
26782958
9.
10.

Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.

Duo-Ji MM, Ci-Ren BS, Long ZW, Zhang XH, Luo DL.

Oncotarget. 2017 Jun 6;8(23):37896-37911. doi: 10.18632/oncotarget.14664.

12.

20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy.

Song S, Song C, Kim HJ, Wu HG, Kim JH, Park NH, Song YS, Kim JW, Kang SB, Ha SW.

Gynecol Oncol. 2012 Jan;124(1):63-7. doi: 10.1016/j.ygyno.2011.09.033. Epub 2011 Oct 18.

PMID:
22004904
13.

Concurrent cisplatin-based chemoradiotherapy versus exclusive radiotherapy in high-risk cervical cancer: a meta-analysis.

Meng XY, Liao Y, Liu XP, Li S, Shi MJ, Zeng XT.

Onco Targets Ther. 2016 Mar 31;9:1875-88. doi: 10.2147/OTT.S97436. eCollection 2016.

14.

[Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].

Sun WZ, Song LP, Zhang YB, Ai T, Lu JL, Ren J, Gao Y.

Nan Fang Yi Ke Da Xue Xue Bao. 2012 Mar;32(3):362-7. Chinese.

PMID:
22445984
15.

Daily low-dose cisplatin-based concurrent chemoradiotherapy in patients with uterine cervical cancer with emphasis on elderly patients: a phase 2 trial.

Mitsuhashi A, Uno T, Usui H, Nishikimi K, Yamamoto N, Watanabe M, Tate S, Hirashiki K, Kato K, Yamazawa K, Shozu M.

Int J Gynecol Cancer. 2013 Oct;23(8):1453-8. doi: 10.1097/IGC.0b013e3182559bda.

PMID:
23266648
16.

Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.

Tsukuda M, Ishitoya J, Matsuda H, Horiuchi C, Taguchi T, Takahashi M, Nishimura G, Kawakami M, Watanabe M, Niho T, Kawano T, Ikeda Y, Sakuma Y, Shiono O, Komatsu M.

Cancer Chemother Pharmacol. 2010 Sep;66(4):729-36. doi: 10.1007/s00280-009-1217-0. Epub 2009 Dec 24.

PMID:
20033810
17.
18.

Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix.

Nagai Y, Toita T, Wakayama A, Nakamoto T, Ooyama T, Tokura A, Inamine M, Kudaka W, Murayama S, Aoki Y.

Anticancer Res. 2012 Apr;32(4):1475-9.

PMID:
22493388
19.

A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.

Oh IJ, Kim KS, Kim YC, Ban HJ, Kwon YS, Kim YI, Lim SC, Chung WK, Nam TK, Song JY, Yoon MS, Ahn SJ.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1247-54. doi: 10.1007/s00280-013-2308-5. Epub 2013 Oct 5.

PMID:
24091849
20.

Outcomes and toxicities for the treatment of stage IVB cervical cancer.

Hwang JH, Lim MC, Seo SS, Kang S, Park SY, Kim JY.

Arch Gynecol Obstet. 2012 Jun;285(6):1685-93. doi: 10.1007/s00404-011-2173-6. Epub 2011 Dec 16.

PMID:
22173823

Supplemental Content

Support Center